Brii Biosciences Announces Upcoming Investor Conferences Participation in June

DURHAM, N.C., and BEIJING, China – May 31, 2023 – Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet need, today announced its participation in the following investor conferences in June 2023. Details of the conferences are as follows:

Goldman Sachs 2023 APAC Healthcare Corporate Day

Investor Meetings: June 26-30, 2023

Location: Hong Kong

Participants: Management team and IR

For more information, please contact your Goldman Sachs representative.

About Brii Bio

Brii Biosciences (“Brii Bio”, stock code: 2137.HK) is a biotechnology company developing therapies to address some of the world’s most common diseases where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious and central nervous system diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs to develop a novel functional cure for hepatitis B viral infection (HBV) and a first-of-its-kind treatment for postpartum depression (PPD). The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.

**Media Inquiry:**[email protected]

**Investor Inquiry:**[email protected]